Medline (MDLN) Cash & Equivalents (2024 - 2026)

Medline (MDLN) has 3 years of Cash & Equivalents data on file, last reported at $2.2 billion in Q1 2026.

• Quarterly Cash & Equivalents changed N/A year-over-year to $2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (changed N/A YoY) and the FY2025 annual result came in at $1.9 billion, up 874.37% from the prior year.
• Cash & Equivalents climbed to $2.2 billion in Q1 2026 per MDLN's latest filing, from $1.9 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $2.2 billion in Q1 2026 and bottomed at $199.0 million in Q4 2024.
• The 3-year median for Cash & Equivalents is $1.9 billion (2025), against an average of $1.5 billion.
• Peak annual rise in Cash & Equivalents reached 874.37% in 2025, while the deepest fall reached 874.37% in 2025.
• Tracing MDLN's Cash & Equivalents over 3 years: stood at $199.0 million in 2024, then jumped by 874.37% to $1.9 billion in 2025, then rose by 15.32% to $2.2 billion in 2026.
• Per Business Quant, the three latest MDLN Cash & Equivalents figures stand at $2.2 billion (Q1 2026), $1.9 billion (Q4 2025), and $199.0 million (Q4 2024).

Peer Comparison